Oncternal (ONCT) - שווי פעילות לרווח לפני ריבית, מסים ופחת
Oncternal Therapeutics operates in the solid and hematological tumor therapy segment, where a shortage of effective solutions persists. The company is developing a unique antibody, ciltuzig, to combat resistant forms of breast and blood cancer by suppressing the ROR1 protein. This EV/EBITDA chart captured the metric at . The team consists of leading oncologists attracted by cutting-edge research and competitive employment terms.
ONCT (oncternal.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The multiple correlates the total enterprise value, including net debt, with operating profit before taxes, depreciation, and amortization. This indicator determines the cost of one dollar of EBITDA, allowing an investor to identify whether an asset is overvalued or undervalued relative to market expectations. For Oncternal Therapeutics (ONCT), which minimizes operational risks through an extensive network of external laboratories, the historical EV/EBITDA trajectory reflects the efficiency of this capital-intensive model.
